Sizing and Forecast
The peanut allergy treatment market size has grown rapidly in recent years. It will grow from $0.41 billion in 2023 to $0.45 billion in 2024 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to increased prevalence, advancements in diagnostic testing, growing public awareness and concern, development of early intervention strategies, and regulatory approvals for peanut allergy treatments.
The peanut allergy treatment market size is expected to see rapid growth in the next few years. It will grow to $0.69 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to a continued rise in the prevalence, expansion of personalized medicine approaches, the introduction of novel immunotherapy treatments, growth in public and private investment, and expansion of telemedicine services. Major trends in the forecast period include the increased adoption of immunotherapy, advancements in biologic therapies, integration of probiotic-based treatments, technological innovations in delivery systems, personalized medicine approaches, and regulatory approvals and support.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/peanut-allergy-treatment-global-market-report
Segmentation & Regional Insights
The peanut allergy treatment market covered in this report is segmented –
1) By Drug Class: Antihistamines, Immunotherapies, Epinephrine, Other Drug Classes
2) By Route Of Administration: Injectable, Oral, Other Routes Of Administration
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels
North America was the largest region in the peanut allergy treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15888&type=smp
Major Driver Impacting Market Growth
The investment in research and development of allergy treatments is expected to propel the growth of the peanut allergy treatment market going forward. Research and development (R&D) investment refers to the financial resources allocated by companies, organizations, or governments toward activities aimed at innovation, product development, and technological advancement. The investment in research and development for allergy treatments is crucial for advancing peanut allergy therapies. This investment fosters the creation of innovative immunotherapies and desensitization techniques, which aim to reduce allergic reactions and improve the quality of life for those affected by peanut allergies. For instance, in January 2024, the Victorian Government announced a strategic $12 million investment in Aravax, an Australia-based clinical-stage biotechnology company, to significantly advance global peanut allergy treatment. This funding is part of a broader $66 million round aimed at developing Aravax’s innovative immunotherapy, PVX108. This initiative has secured Phase 2 trial approvals from both the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), underscoring its potential impact on public health worldwide. Therefore, investment in research and development of allergy treatments is driving the growth of the peanut allergy treatment market.
Key Industry Players
Major companies operating in the peanut allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Hikma Pharmaceuticals plc, ALK-Abelló A/S, Amneal Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc, Stallergenes Greer plc, kaleo Inc., Aquestive Therapeutics Inc., Vedanta Biosciences Inc., Aimmune Therapeutics Inc., AnaptysBio Inc., Alladapt Immunotherapeutics Inc., Aravax Pty Ltd, Intrommune Therapeutics Inc., IgGenix Inc., DBV Technologies SA, Camallergy Ltd., HAL Allergy Group, Prota Therapeutics Pty Ltd.
The peanut allergy treatment market report table of contents includes:
1. Executive Summary
2. Peanut Allergy Treatment Market Characteristics
3. Peanut Allergy Treatment Market Trends And Strategies
4. Peanut Allergy Treatment Market – Macro Economic Scenario
5. Global Peanut Allergy Treatment Market Size and Growth
…
32. Global Peanut Allergy Treatment Market Competitive Benchmarking
33. Global Peanut Allergy Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Peanut Allergy Treatment Market
35. Peanut Allergy Treatment Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
